Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir
The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-lik...
Saved in:
| Published in | Nature communications Vol. 14; no. 1; pp. 6463 - 15 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
13.10.2023
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-like protease (3CL
pro
) inhibitor, namely simnotrelvir, and its preclinical evaluation, which lay the foundation for clinical trials studies as well as the conditional approval of simnotrelvir in combination with ritonavir for the treatment of COVID-19. The structure-based optimization of boceprevir, an approved HCV protease inhibitor, leads to identification of simnotrelvir that covalently inhibits SARS-CoV-2 3CL
pro
with an enthalpy-driven thermodynamic binding signature. Multiple enzymatic assays reveal that simnotrelvir is a potent pan-CoV 3CL
pro
inhibitor but has high selectivity. It effectively blocks replications of SARS-CoV-2 variants in cell-based assays and exhibits good pharmacokinetic and safety profiles in male and female rats and monkeys, leading to robust oral efficacy in a male mouse model of SARS-CoV-2 Delta infection in which it not only significantly reduces lung viral loads but also eliminates the virus from brains. The discovery of simnotrelvir thereby highlights the utility of structure-based development of marked protease inhibitors for providing a small molecule therapeutic effectively combatting human coronaviruses.
In this study, the authors report the structure-based discovery and preclinical evaluation of 2 simnotrelvir, an orally bioavailable 3CLpro inhibitor that blocks replication of SARS-CoV-2 variants in 3 vitro, shows robust efficacy in a mouse model and good safety and pharmacokinetic profiles in rats 4 and monkeys. |
|---|---|
| AbstractList | The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-like protease (3CL
pro
) inhibitor, namely simnotrelvir, and its preclinical evaluation, which lay the foundation for clinical trials studies as well as the conditional approval of simnotrelvir in combination with ritonavir for the treatment of COVID-19. The structure-based optimization of boceprevir, an approved HCV protease inhibitor, leads to identification of simnotrelvir that covalently inhibits SARS-CoV-2 3CL
pro
with an enthalpy-driven thermodynamic binding signature. Multiple enzymatic assays reveal that simnotrelvir is a potent pan-CoV 3CL
pro
inhibitor but has high selectivity. It effectively blocks replications of SARS-CoV-2 variants in cell-based assays and exhibits good pharmacokinetic and safety profiles in male and female rats and monkeys, leading to robust oral efficacy in a male mouse model of SARS-CoV-2 Delta infection in which it not only significantly reduces lung viral loads but also eliminates the virus from brains. The discovery of simnotrelvir thereby highlights the utility of structure-based development of marked protease inhibitors for providing a small molecule therapeutic effectively combatting human coronaviruses. The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-like protease (3CLpro) inhibitor, namely simnotrelvir, and its preclinical evaluation, which lay the foundation for clinical trials studies as well as the conditional approval of simnotrelvir in combination with ritonavir for the treatment of COVID-19. The structure-based optimization of boceprevir, an approved HCV protease inhibitor, leads to identification of simnotrelvir that covalently inhibits SARS-CoV-2 3CLpro with an enthalpy-driven thermodynamic binding signature. Multiple enzymatic assays reveal that simnotrelvir is a potent pan-CoV 3CLpro inhibitor but has high selectivity. It effectively blocks replications of SARS-CoV-2 variants in cell-based assays and exhibits good pharmacokinetic and safety profiles in male and female rats and monkeys, leading to robust oral efficacy in a male mouse model of SARS-CoV-2 Delta infection in which it not only significantly reduces lung viral loads but also eliminates the virus from brains. The discovery of simnotrelvir thereby highlights the utility of structure-based development of marked protease inhibitors for providing a small molecule therapeutic effectively combatting human coronaviruses.The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-like protease (3CLpro) inhibitor, namely simnotrelvir, and its preclinical evaluation, which lay the foundation for clinical trials studies as well as the conditional approval of simnotrelvir in combination with ritonavir for the treatment of COVID-19. The structure-based optimization of boceprevir, an approved HCV protease inhibitor, leads to identification of simnotrelvir that covalently inhibits SARS-CoV-2 3CLpro with an enthalpy-driven thermodynamic binding signature. Multiple enzymatic assays reveal that simnotrelvir is a potent pan-CoV 3CLpro inhibitor but has high selectivity. It effectively blocks replications of SARS-CoV-2 variants in cell-based assays and exhibits good pharmacokinetic and safety profiles in male and female rats and monkeys, leading to robust oral efficacy in a male mouse model of SARS-CoV-2 Delta infection in which it not only significantly reduces lung viral loads but also eliminates the virus from brains. The discovery of simnotrelvir thereby highlights the utility of structure-based development of marked protease inhibitors for providing a small molecule therapeutic effectively combatting human coronaviruses. The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-like protease (3CL pro ) inhibitor, namely simnotrelvir, and its preclinical evaluation, which lay the foundation for clinical trials studies as well as the conditional approval of simnotrelvir in combination with ritonavir for the treatment of COVID-19. The structure-based optimization of boceprevir, an approved HCV protease inhibitor, leads to identification of simnotrelvir that covalently inhibits SARS-CoV-2 3CL pro with an enthalpy-driven thermodynamic binding signature. Multiple enzymatic assays reveal that simnotrelvir is a potent pan-CoV 3CL pro inhibitor but has high selectivity. It effectively blocks replications of SARS-CoV-2 variants in cell-based assays and exhibits good pharmacokinetic and safety profiles in male and female rats and monkeys, leading to robust oral efficacy in a male mouse model of SARS-CoV-2 Delta infection in which it not only significantly reduces lung viral loads but also eliminates the virus from brains. The discovery of simnotrelvir thereby highlights the utility of structure-based development of marked protease inhibitors for providing a small molecule therapeutic effectively combatting human coronaviruses. In this study, the authors report the structure-based discovery and preclinical evaluation of 2 simnotrelvir, an orally bioavailable 3CLpro inhibitor that blocks replication of SARS-CoV-2 variants in 3 vitro, shows robust efficacy in a mouse model and good safety and pharmacokinetic profiles in rats 4 and monkeys. Abstract The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-like protease (3CLpro) inhibitor, namely simnotrelvir, and its preclinical evaluation, which lay the foundation for clinical trials studies as well as the conditional approval of simnotrelvir in combination with ritonavir for the treatment of COVID-19. The structure-based optimization of boceprevir, an approved HCV protease inhibitor, leads to identification of simnotrelvir that covalently inhibits SARS-CoV-2 3CLpro with an enthalpy-driven thermodynamic binding signature. Multiple enzymatic assays reveal that simnotrelvir is a potent pan-CoV 3CLpro inhibitor but has high selectivity. It effectively blocks replications of SARS-CoV-2 variants in cell-based assays and exhibits good pharmacokinetic and safety profiles in male and female rats and monkeys, leading to robust oral efficacy in a male mouse model of SARS-CoV-2 Delta infection in which it not only significantly reduces lung viral loads but also eliminates the virus from brains. The discovery of simnotrelvir thereby highlights the utility of structure-based development of marked protease inhibitors for providing a small molecule therapeutic effectively combatting human coronaviruses. The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-like protease (3CLpro) inhibitor, namely simnotrelvir, and its preclinical evaluation, which lay the foundation for clinical trials studies as well as the conditional approval of simnotrelvir in combination with ritonavir for the treatment of COVID-19. The structure-based optimization of boceprevir, an approved HCV protease inhibitor, leads to identification of simnotrelvir that covalently inhibits SARS-CoV-2 3CLpro with an enthalpy-driven thermodynamic binding signature. Multiple enzymatic assays reveal that simnotrelvir is a potent pan-CoV 3CLpro inhibitor but has high selectivity. It effectively blocks replications of SARS-CoV-2 variants in cell-based assays and exhibits good pharmacokinetic and safety profiles in male and female rats and monkeys, leading to robust oral efficacy in a male mouse model of SARS-CoV-2 Delta infection in which it not only significantly reduces lung viral loads but also eliminates the virus from brains. The discovery of simnotrelvir thereby highlights the utility of structure-based development of marked protease inhibitors for providing a small molecule therapeutic effectively combatting human coronaviruses.In this study, the authors report the structure-based discovery and preclinical evaluation of 2 simnotrelvir, an orally bioavailable 3CLpro inhibitor that blocks replication of SARS-CoV-2 variants in 3 vitro, shows robust efficacy in a mouse model and good safety and pharmacokinetic profiles in rats 4 and monkeys. The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-like protease (3CL ) inhibitor, namely simnotrelvir, and its preclinical evaluation, which lay the foundation for clinical trials studies as well as the conditional approval of simnotrelvir in combination with ritonavir for the treatment of COVID-19. The structure-based optimization of boceprevir, an approved HCV protease inhibitor, leads to identification of simnotrelvir that covalently inhibits SARS-CoV-2 3CL with an enthalpy-driven thermodynamic binding signature. Multiple enzymatic assays reveal that simnotrelvir is a potent pan-CoV 3CL inhibitor but has high selectivity. It effectively blocks replications of SARS-CoV-2 variants in cell-based assays and exhibits good pharmacokinetic and safety profiles in male and female rats and monkeys, leading to robust oral efficacy in a male mouse model of SARS-CoV-2 Delta infection in which it not only significantly reduces lung viral loads but also eliminates the virus from brains. The discovery of simnotrelvir thereby highlights the utility of structure-based development of marked protease inhibitors for providing a small molecule therapeutic effectively combatting human coronaviruses. |
| ArticleNumber | 6463 |
| Author | Su, Haixia Huang, Xiaoxing Jiang, Xiangrui Xu, Yechun Shang, Weijuan Zhang, Qiumeng Xie, Hang Jiang, Lei Shen, Jingshan Peng, Shaoping Zhao, Wenfeng Xiong, Muya Zhou, Feng Chen, Ping Yang, Feipu Zhang, Leike Li, Minjun Zhang, Yan Nie, Tianqing Xiao, Gengfu Tang, Renhong Jiang, Hualiang |
| Author_xml | – sequence: 1 givenname: Xiangrui surname: Jiang fullname: Jiang, Xiangrui organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences – sequence: 2 givenname: Haixia surname: Su fullname: Su, Haixia organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences – sequence: 3 givenname: Weijuan surname: Shang fullname: Shang, Weijuan organization: State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences – sequence: 4 givenname: Feng orcidid: 0009-0007-3050-6239 surname: Zhou fullname: Zhou, Feng organization: State Key Laboratory of Neurology and Oncology Drug Development, Simcere Zaiming Pharmaceutical Co., Ltd – sequence: 5 givenname: Yan surname: Zhang fullname: Zhang, Yan organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences – sequence: 6 givenname: Wenfeng surname: Zhao fullname: Zhao, Wenfeng organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences – sequence: 7 givenname: Qiumeng surname: Zhang fullname: Zhang, Qiumeng organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences – sequence: 8 givenname: Hang surname: Xie fullname: Xie, Hang organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, School of Chinese Materia Medica, Nanjing University of Chinese Medicine – sequence: 9 givenname: Lei surname: Jiang fullname: Jiang, Lei organization: Simcere Zaiming Pharmaceutical Co., Ltd – sequence: 10 givenname: Tianqing surname: Nie fullname: Nie, Tianqing organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, School of Chinese Materia Medica, Nanjing University of Chinese Medicine – sequence: 11 givenname: Feipu surname: Yang fullname: Yang, Feipu organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences – sequence: 12 givenname: Muya surname: Xiong fullname: Xiong, Muya organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences – sequence: 13 givenname: Xiaoxing surname: Huang fullname: Huang, Xiaoxing organization: Simcere Zaiming Pharmaceutical Co., Ltd – sequence: 14 givenname: Minjun surname: Li fullname: Li, Minjun organization: Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences – sequence: 15 givenname: Ping surname: Chen fullname: Chen, Ping organization: Jiangsu Simcere Pharmaceutical Co., Ltd – sequence: 16 givenname: Shaoping surname: Peng fullname: Peng, Shaoping organization: State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Pharmaceutical Co., Ltd – sequence: 17 givenname: Gengfu orcidid: 0000-0001-9401-235X surname: Xiao fullname: Xiao, Gengfu organization: State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences – sequence: 18 givenname: Hualiang orcidid: 0000-0003-0656-6315 surname: Jiang fullname: Jiang, Hualiang organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences – sequence: 19 givenname: Renhong surname: Tang fullname: Tang, Renhong email: renhong.tang@simceregroup.com organization: State Key Laboratory of Neurology and Oncology Drug Development, Simcere Zaiming Pharmaceutical Co., Ltd – sequence: 20 givenname: Leike orcidid: 0000-0002-2593-2571 surname: Zhang fullname: Zhang, Leike email: zhangleike@wh.iov.cn organization: State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Hubei jiangxia Laboratory – sequence: 21 givenname: Jingshan orcidid: 0000-0001-9679-9934 surname: Shen fullname: Shen, Jingshan email: shenjingshan@simm.ac.cn organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences – sequence: 22 givenname: Yechun orcidid: 0000-0002-1581-6155 surname: Xu fullname: Xu, Yechun email: ycxu@simm.ac.cn organization: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, University of Chinese Academy of Sciences, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37833261$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1vEzEQhleoiJbSP8ABrcSFi8Gf6_UJVREflSohEeBqeb2ziYNjB9sbKf8etyml5YAvtmbeecYzep83JyEGaJqXBL8lmPXvMie8kwhThjglmKLDk-aMYk4QkZSdPHifNhc5b3A9TJGe82fNKZM9Y7QjZ81uWdJsy5wADSbD2I6wBx93WwilNWFsdwmsd8FZ41vYGz-b4mJo49SWNbTLy69LtIg_EG3ZAnn3E2pBLFBRrQtrN7gSU5vdNsSSwO9detE8nYzPcHF3nzffP374tviMrr98ulpcXiMrOClIWCv6iVpJJywGY4m11EyqU0IMQCyjQ9-RUQlrxjqLUKbrB26I7NjIexiAnTdXR-4YzUbvktuadNDROH0biGmlTSrOetCG9iAsVoT1lEtClZUK1y6U8cqbxsp6f2Tt5mELo627ScY_gj7OBLfWq7jXBAspFCWV8OaOkOKvGXLRW5cteG8CxDlr2kvJpFK0q9LX_0g3cU6h7upG1UnFJBFVRY8qm2LOCab73xCsbwyijwbR1SD61iD6UItePZzjvuSPHaqAHQW5psIK0t_e_8H-BtzLyQg |
| CitedBy_id | crossref_primary_10_1021_acsptsci_3c00313 crossref_primary_10_1021_acs_jmedchem_3c01938 crossref_primary_10_3390_molecules29010225 crossref_primary_10_1016_j_bioorg_2023_107001 crossref_primary_10_1016_j_bmcl_2023_129547 crossref_primary_10_1056_NEJMoa2301425 crossref_primary_10_1021_acs_jafc_4c01942 crossref_primary_10_1039_D4RA02029D crossref_primary_10_1021_acs_jmedchem_4c01342 crossref_primary_10_1039_D3MD00493G crossref_primary_10_1039_D4SC01027B crossref_primary_10_1080_14656566_2024_2323597 crossref_primary_10_1038_s41421_024_00673_0 crossref_primary_10_1126_scitranslmed_adi0979 crossref_primary_10_1021_acs_oprd_3c00494 crossref_primary_10_1021_acs_jmedchem_3c02469 crossref_primary_10_1021_acs_jmedchem_3c01876 crossref_primary_10_3390_v16060844 |
| Cites_doi | 10.1016/j.drudis.2014.09.014 10.1021/acscatal.8b05051 10.1107/S0907444902016657 10.1016/j.str.2020.10.007 10.1038/s41573-022-00542-z 10.1126/science.abd0831 10.1126/science.abl4784 10.1007/s41365-019-0683-2 10.1107/S1600576719001183 10.1107/S0907444904019158 10.1038/s41467-020-18233-x 10.1038/s41401-020-0483-6 10.1038/s41467-022-29915-z 10.1021/acs.jmedchem.5b01461 10.1016/j.drudis.2008.07.005 10.1021/acs.jmedchem.0c01063 10.1038/s41586-020-2223-y 10.1107/S0907444994003112 10.1021/acs.jmedchem.2c00624 10.1107/S0907444906019949 10.1021/acs.jmedchem.0c01140 10.1021/ar700109k 10.1038/nrd3845 10.1126/science.abb4489 10.1002/med.21783 10.1128/JVI.01819-20 10.1016/j.ab.2016.08.023 10.1126/science.abf1611 10.1111/febs.12936 10.1016/j.jbbm.2005.12.008 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. Springer Nature Limited. The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Springer Nature Limited 2023 |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. Springer Nature Limited. – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Springer Nature Limited 2023 |
| DBID | C6C CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PIMPY PQEST PQQKQ PQUKI RC3 SOI 7X8 5PM DOA |
| DOI | 10.1038/s41467-023-42102-y |
| DatabaseName | SpringerOpen Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management Health Research Premium Collection Natural Science Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts Technology Collection Technology Research Database ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2041-1723 |
| EndPage | 15 |
| ExternalDocumentID | oai_doaj_org_article_a28e5c09138247129c790be1234763fd 10_1038_s41467_023_42102_y 37833261 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Shanghai Science and Technology Development Foundation (Shanghai Science and Technology Development Fund) grantid: No. 22YF1457300 funderid: https://doi.org/10.13039/100012543 – fundername: ; grantid: No. 22YF1457300 |
| GroupedDBID | --- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADRAZ AENEX AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LGEZI LK8 LOTEE M1P M48 M7P M~E NADUK NAO NXXTH O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PQEST PQUKI RC3 SOI 7X8 5PM |
| ID | FETCH-LOGICAL-c541t-5cc58f2c72f05bac1cc2af96955be1c32b861d95cad78359a68b4a1763d48ebe3 |
| IEDL.DBID | RPM |
| ISSN | 2041-1723 |
| IngestDate | Tue Oct 22 14:57:26 EDT 2024 Tue Sep 17 21:29:24 EDT 2024 Sat Oct 26 01:54:04 EDT 2024 Sat Nov 09 03:01:41 EST 2024 Thu Nov 21 23:29:52 EST 2024 Sat Nov 02 12:26:16 EDT 2024 Fri Oct 11 20:46:25 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2023. Springer Nature Limited. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-5cc58f2c72f05bac1cc2af96955be1c32b861d95cad78359a68b4a1763d48ebe3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0009-0007-3050-6239 0000-0001-9401-235X 0000-0001-9679-9934 0000-0002-1581-6155 0000-0002-2593-2571 0000-0003-0656-6315 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575921/ |
| PMID | 37833261 |
| PQID | 2876793715 |
| PQPubID | 546298 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a28e5c09138247129c790be1234763fd pubmedcentral_primary_oai_pubmedcentral_nih_gov_10575921 proquest_miscellaneous_2877379926 proquest_journals_2876793715 crossref_primary_10_1038_s41467_023_42102_y pubmed_primary_37833261 springer_journals_10_1038_s41467_023_42102_y |
| PublicationCentury | 2000 |
| PublicationDate | 2023-10-13 |
| PublicationDateYYYYMMDD | 2023-10-13 |
| PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature communications |
| PublicationTitleAbbrev | Nat Commun |
| PublicationTitleAlternate | Nat Commun |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | de Vries (CR14) 2021; 95 Bowes (CR19) 2012; 11 Dai (CR6) 2020; 368 Schon, Freire (CR16) 2016; 513 Freire (CR17) 2008; 13 Tarcsay, Keseru (CR15) 2015; 20 Su (CR29) 2020; 41 Kneller (CR8) 2020; 28 Adams (CR31) 2002; 58 Cannalire (CR13) 2022; 65 van den Ent, Lowe (CR24) 2006; 67 Fu (CR9) 2020; 11 Su, Xu, Jiang (CR1) 2021; 1 Tyndall (CR5) 2022; 65 Emsley, Cowtan (CR30) 2004; 60 Qiao (CR20) 2021; 371 Owen (CR4) 2021; 374 Xiong (CR2) 2021; 41 Hoffman (CR10) 2020; 63 Minor (CR27) 2006; 62 Boike, Henning, Nomura (CR23) 2022; 21 Zhang (CR25) 2019; 30 Hilgenfeld (CR11) 2014; 281 Njoroge (CR7) 2008; 41 Wang (CR22) 2019; 9 Baum (CR3) 2020; 369 Jin (CR18) 2020; 582 Yu (CR26) 2019; 52 Kneller (CR21) 2022; 13 (CR28) 1994; 50 Pillaiyar (CR12) 2016; 59 J Bowes (42102_CR19) 2012; 11 R Hilgenfeld (42102_CR11) 2014; 281 H Su (42102_CR29) 2020; 41 YH Wang (42102_CR22) 2019; 9 R Cannalire (42102_CR13) 2022; 65 M Xiong (42102_CR2) 2021; 41 L Fu (42102_CR9) 2020; 11 A Tarcsay (42102_CR15) 2015; 20 A Schon (42102_CR16) 2016; 513 A Baum (42102_CR3) 2020; 369 DW Kneller (42102_CR21) 2022; 13 DW Kneller (42102_CR8) 2020; 28 FG Njoroge (42102_CR7) 2008; 41 Z Jin (42102_CR18) 2020; 582 J Qiao (42102_CR20) 2021; 371 M de Vries (42102_CR14) 2021; 95 RL Hoffman (42102_CR10) 2020; 63 F Yu (42102_CR26) 2019; 52 L Boike (42102_CR23) 2022; 21 Collaborative C. P. (42102_CR28) 1994; 50 JDA Tyndall (42102_CR5) 2022; 65 E Freire (42102_CR17) 2008; 13 P Emsley (42102_CR30) 2004; 60 T Pillaiyar (42102_CR12) 2016; 59 H Su (42102_CR1) 2021; 1 DR Owen (42102_CR4) 2021; 374 W Zhang (42102_CR25) 2019; 30 PD Adams (42102_CR31) 2002; 58 W Dai (42102_CR6) 2020; 368 F van den Ent (42102_CR24) 2006; 67 W Minor (42102_CR27) 2006; 62 |
| References_xml | – volume: 20 start-page: 86 year: 2015 end-page: 94 ident: CR15 article-title: Is there a link between selectivity and binding thermodynamics profiles? publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2014.09.014 contributor: fullname: Keseru – volume: 9 start-page: 2292 year: 2019 end-page: 2302 ident: CR22 article-title: Covalent inhibition mechanism of antidiabetic drugs-vildagliptin vs saxagliptin publication-title: Acs Catal. doi: 10.1021/acscatal.8b05051 contributor: fullname: Wang – volume: 58 start-page: 1948 year: 2002 end-page: 1954 ident: CR31 article-title: PHENIX: building new software for automated crystallographic structure determination publication-title: Acta Crystallogr. D doi: 10.1107/S0907444902016657 contributor: fullname: Adams – volume: 28 start-page: 1313 year: 2020 end-page: 1320 ident: CR8 article-title: Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals publication-title: Structure doi: 10.1016/j.str.2020.10.007 contributor: fullname: Kneller – volume: 21 start-page: 881 year: 2022 end-page: 898 ident: CR23 article-title: Advances in covalent drug discovery publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-022-00542-z contributor: fullname: Nomura – volume: 369 start-page: 1014 year: 2020 end-page: 1018 ident: CR3 article-title: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies publication-title: Science doi: 10.1126/science.abd0831 contributor: fullname: Baum – volume: 374 start-page: 1586 year: 2021 end-page: 1593 ident: CR4 article-title: An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 publication-title: Science doi: 10.1126/science.abl4784 contributor: fullname: Owen – volume: 30 start-page: 170 year: 2019 ident: CR25 article-title: The protein complex crystallography beamline (BL19U1) at the shanghai synchrotron radiation facility publication-title: Nucl. Sci. Tech. doi: 10.1007/s41365-019-0683-2 contributor: fullname: Zhang – volume: 52 start-page: 472 year: 2019 end-page: 477 ident: CR26 article-title: Aquarium: an automatic data-processing and experiment information management system for biological macromolecular crystallography beamlines publication-title: J. Appl. Crystallogr. doi: 10.1107/S1600576719001183 contributor: fullname: Yu – volume: 60 start-page: 2126 year: 2004 end-page: 2132 ident: CR30 article-title: Coot: model-building tools for molecular graphics publication-title: Acta Crystallogr. D doi: 10.1107/S0907444904019158 contributor: fullname: Cowtan – volume: 11 year: 2020 ident: CR9 article-title: Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease publication-title: Nat. Commun. doi: 10.1038/s41467-020-18233-x contributor: fullname: Fu – volume: 41 start-page: 1167 year: 2020 end-page: 1177 ident: CR29 article-title: Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients publication-title: Acta Pharmacol. Sin. doi: 10.1038/s41401-020-0483-6 contributor: fullname: Su – volume: 13 year: 2022 ident: CR21 article-title: Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease publication-title: Nat. Commun. doi: 10.1038/s41467-022-29915-z contributor: fullname: Kneller – volume: 59 start-page: 6595 year: 2016 end-page: 6628 ident: CR12 article-title: An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.5b01461 contributor: fullname: Pillaiyar – volume: 13 start-page: 869 year: 2008 end-page: 874 ident: CR17 article-title: Do enthalpy and entropy distinguish first in class from best in class? publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2008.07.005 contributor: fullname: Freire – volume: 63 start-page: 12725 year: 2020 end-page: 12747 ident: CR10 article-title: Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.0c01063 contributor: fullname: Hoffman – volume: 582 start-page: 289 year: 2020 end-page: 293 ident: CR18 article-title: Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors publication-title: Nature doi: 10.1038/s41586-020-2223-y contributor: fullname: Jin – volume: 50 start-page: 760 year: 1994 end-page: 763 ident: CR28 article-title: The CCP4 suite: programs for protein crystallography publication-title: Acta Crystallogr. D doi: 10.1107/S0907444994003112 – volume: 65 start-page: 6496 year: 2022 end-page: 6498 ident: CR5 article-title: S-217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV-2 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.2c00624 contributor: fullname: Tyndall – volume: 62 start-page: 859 year: 2006 end-page: 866 ident: CR27 article-title: HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes publication-title: Acta Crystallogr. D doi: 10.1107/S0907444906019949 contributor: fullname: Minor – volume: 1 start-page: 151 year: 2021 end-page: 165 ident: CR1 article-title: Drug discovery and development targeting the life cycle of SARS-CoV-2 publication-title: Fund. Res. contributor: fullname: Jiang – volume: 65 start-page: 2716 year: 2022 end-page: 2746 ident: CR13 article-title: Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.0c01140 contributor: fullname: Cannalire – volume: 41 start-page: 50 year: 2008 end-page: 59 ident: CR7 article-title: Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection publication-title: Acc. Chem. Res. doi: 10.1021/ar700109k contributor: fullname: Njoroge – volume: 11 start-page: 909 year: 2012 end-page: 922 ident: CR19 article-title: Reducing safety-related drug attrition: the use of in vitro pharmacological profiling publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd3845 contributor: fullname: Bowes – volume: 368 start-page: 1331 year: 2020 end-page: 1335 ident: CR6 article-title: Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease publication-title: Science doi: 10.1126/science.abb4489 contributor: fullname: Dai – volume: 41 start-page: 1965 year: 2021 end-page: 1998 ident: CR2 article-title: What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design publication-title: Med. Res. Rev. doi: 10.1002/med.21783 contributor: fullname: Xiong – volume: 95 start-page: e01819 year: 2021 ident: CR14 article-title: A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19 publication-title: J. Virol. doi: 10.1128/JVI.01819-20 contributor: fullname: de Vries – volume: 513 start-page: 1 year: 2016 end-page: 6 ident: CR16 article-title: Enthalpy screen of drug candidates publication-title: Anal. Biochem. doi: 10.1016/j.ab.2016.08.023 contributor: fullname: Freire – volume: 371 start-page: 1374 year: 2021 end-page: 1378 ident: CR20 article-title: SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model publication-title: Science doi: 10.1126/science.abf1611 contributor: fullname: Qiao – volume: 281 start-page: 4085 year: 2014 end-page: 4096 ident: CR11 article-title: From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design publication-title: FEBS J. doi: 10.1111/febs.12936 contributor: fullname: Hilgenfeld – volume: 67 start-page: 67 year: 2006 end-page: 74 ident: CR24 article-title: RF cloning: a restriction-free method for inserting target genes into plasmids publication-title: J. Biochem. Biophys. Methods doi: 10.1016/j.jbbm.2005.12.008 contributor: fullname: Lowe – volume: 65 start-page: 2716 year: 2022 ident: 42102_CR13 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.0c01140 contributor: fullname: R Cannalire – volume: 13 year: 2022 ident: 42102_CR21 publication-title: Nat. Commun. doi: 10.1038/s41467-022-29915-z contributor: fullname: DW Kneller – volume: 41 start-page: 1965 year: 2021 ident: 42102_CR2 publication-title: Med. Res. Rev. doi: 10.1002/med.21783 contributor: fullname: M Xiong – volume: 65 start-page: 6496 year: 2022 ident: 42102_CR5 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.2c00624 contributor: fullname: JDA Tyndall – volume: 30 start-page: 170 year: 2019 ident: 42102_CR25 publication-title: Nucl. Sci. Tech. doi: 10.1007/s41365-019-0683-2 contributor: fullname: W Zhang – volume: 60 start-page: 2126 year: 2004 ident: 42102_CR30 publication-title: Acta Crystallogr. D doi: 10.1107/S0907444904019158 contributor: fullname: P Emsley – volume: 1 start-page: 151 year: 2021 ident: 42102_CR1 publication-title: Fund. Res. contributor: fullname: H Su – volume: 513 start-page: 1 year: 2016 ident: 42102_CR16 publication-title: Anal. Biochem. doi: 10.1016/j.ab.2016.08.023 contributor: fullname: A Schon – volume: 28 start-page: 1313 year: 2020 ident: 42102_CR8 publication-title: Structure doi: 10.1016/j.str.2020.10.007 contributor: fullname: DW Kneller – volume: 9 start-page: 2292 year: 2019 ident: 42102_CR22 publication-title: Acs Catal. doi: 10.1021/acscatal.8b05051 contributor: fullname: YH Wang – volume: 21 start-page: 881 year: 2022 ident: 42102_CR23 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-022-00542-z contributor: fullname: L Boike – volume: 41 start-page: 1167 year: 2020 ident: 42102_CR29 publication-title: Acta Pharmacol. Sin. doi: 10.1038/s41401-020-0483-6 contributor: fullname: H Su – volume: 281 start-page: 4085 year: 2014 ident: 42102_CR11 publication-title: FEBS J. doi: 10.1111/febs.12936 contributor: fullname: R Hilgenfeld – volume: 58 start-page: 1948 year: 2002 ident: 42102_CR31 publication-title: Acta Crystallogr. D doi: 10.1107/S0907444902016657 contributor: fullname: PD Adams – volume: 52 start-page: 472 year: 2019 ident: 42102_CR26 publication-title: J. Appl. Crystallogr. doi: 10.1107/S1600576719001183 contributor: fullname: F Yu – volume: 11 year: 2020 ident: 42102_CR9 publication-title: Nat. Commun. doi: 10.1038/s41467-020-18233-x contributor: fullname: L Fu – volume: 20 start-page: 86 year: 2015 ident: 42102_CR15 publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2014.09.014 contributor: fullname: A Tarcsay – volume: 95 start-page: e01819 year: 2021 ident: 42102_CR14 publication-title: J. Virol. doi: 10.1128/JVI.01819-20 contributor: fullname: M de Vries – volume: 67 start-page: 67 year: 2006 ident: 42102_CR24 publication-title: J. Biochem. Biophys. Methods doi: 10.1016/j.jbbm.2005.12.008 contributor: fullname: F van den Ent – volume: 374 start-page: 1586 year: 2021 ident: 42102_CR4 publication-title: Science doi: 10.1126/science.abl4784 contributor: fullname: DR Owen – volume: 62 start-page: 859 year: 2006 ident: 42102_CR27 publication-title: Acta Crystallogr. D doi: 10.1107/S0907444906019949 contributor: fullname: W Minor – volume: 371 start-page: 1374 year: 2021 ident: 42102_CR20 publication-title: Science doi: 10.1126/science.abf1611 contributor: fullname: J Qiao – volume: 50 start-page: 760 year: 1994 ident: 42102_CR28 publication-title: Acta Crystallogr. D doi: 10.1107/S0907444994003112 contributor: fullname: Collaborative C. P. – volume: 369 start-page: 1014 year: 2020 ident: 42102_CR3 publication-title: Science doi: 10.1126/science.abd0831 contributor: fullname: A Baum – volume: 59 start-page: 6595 year: 2016 ident: 42102_CR12 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.5b01461 contributor: fullname: T Pillaiyar – volume: 582 start-page: 289 year: 2020 ident: 42102_CR18 publication-title: Nature doi: 10.1038/s41586-020-2223-y contributor: fullname: Z Jin – volume: 368 start-page: 1331 year: 2020 ident: 42102_CR6 publication-title: Science doi: 10.1126/science.abb4489 contributor: fullname: W Dai – volume: 13 start-page: 869 year: 2008 ident: 42102_CR17 publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2008.07.005 contributor: fullname: E Freire – volume: 41 start-page: 50 year: 2008 ident: 42102_CR7 publication-title: Acc. Chem. Res. doi: 10.1021/ar700109k contributor: fullname: FG Njoroge – volume: 63 start-page: 12725 year: 2020 ident: 42102_CR10 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.0c01063 contributor: fullname: RL Hoffman – volume: 11 start-page: 909 year: 2012 ident: 42102_CR19 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd3845 contributor: fullname: J Bowes |
| SSID | ssj0000391844 |
| Score | 2.6272726 |
| Snippet | The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants... Abstract The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants... |
| SourceID | doaj pubmedcentral proquest crossref pubmed springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 6463 |
| SubjectTerms | 631/326/22/1295 631/326/596/4130 692/308/153 692/699/255/2514 82/83 Animals Antiviral Agents - chemistry Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Bioavailability Clinical trials Coronaviruses COVID-19 Effectiveness Enthalpy Enzyme Inhibitors Female Humanities and Social Sciences Humans Male Males Mice Monkeys multidisciplinary Optimization Pandemics Pharmacokinetics Pharmacology Protease Protease inhibitors Protease Inhibitors - chemistry Protease Inhibitors - pharmacology Protease Inhibitors - therapeutic use Proteinase inhibitors Rats Ritonavir Robustness Safety SARS-CoV-2 Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 Viral diseases |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1baxQxFA5SEHwR745WieCbhmZy2-SxLpYi6INrpW8hkwsdrDPL7raw_74nmdndrhd88XUyGQ7nnsk530HorVKSCwXKG7VIRATuiaEqNzAnprhTRrHc4Pz5izo9E5_O5fmtUV-5JmyABx4Yd-SYjtJn9ErNwJEy4yeGNhEcrgDTSKF4X8puHaaKD-YGji5i7JKhXB8tRfEJEKKIyBvIei8SFcD-P2WZvxdL_nJjWgLRyQN0f8wg8fFA-UN0J3aP0N1hpuT6MZrPCiLs1SKSHKECDruyIOy6gOfg48Z2SLzD-sZ9wpAL4tnx1xmZ9t8Jw3xKLtsfERcoB_gUbruLtgEPsMDL9mfXrxbx8rpdPEFnJx-_TU_JOFaBeCnqFZHeS52Yn7BEZeN87T1zySgjJfDVc9ZoVQcjvQv5t5BxSjfC1cDtIDTInD9FB13fxecIM183taJJO0VFctQFDxbtuDJa0hhphd5tWGznA3qGLbfeXNtBIBYEYotA7LpCH7IUtm9m5OvyAPTBjvpg_6UPFTrcyNCO5ri0cCxUGQiwlhV6s10GQ8q3I66L_VV5Z8InxjBVoWeDyLeUcGAE5Ll1hfSeMuyRur_StRcFrDvPUZaGwdb3G73Z0fV3Xrz4H7x4ie6xrPC5AIcfogPQv_gKcqhV87qYyw329BZB priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgERIXxJvAgozEDayNn7FPaKkoKyQ4UBbtzXJsZzdiSUraReq_Z-ymrcrrGifRxPPMzPgbhF4qJblQILxRi4aIwD0xpUoHmBumuFNGsXTA-eMndXIqPpzJszHhthjbKjc2MRvq0PuUIz-CyF4lLDcq38x_kDQ1KlVXxxEa19ENyiqVWvr09P02x5LQz7UQ41mZkuujhciWARwVEelnh6z2_FGG7f9brPlny-RvddPsjqZ30O0xjsTHa8bfRddidw_dXE-WXN1H81nGhb0aIkl-KuCwaw7Crgt4DpZuPBSJd4jfuG8wRIR4dvx5Rib9V8Iwn5DL9lvEGdABXoXb7qKtwQ4MeNF-7_rlEC9_tsMDdDp992VyQsbhCsRLQZdEei91w3zFmlLWzlPvmWuMMlLWkXrOaq1oMNK7kJJDxildC0fBHAWhgfP8ITro-i4-Rph5WlNVNtqpUjSudMGDXjuujJZljGWBXm222M7XGBo21765tmuGWGCIzQyxqwK9TVzY3pnwr_OFfji3ozpZx3SUPmGaagbulRlfmRLoZlwAhU0o0OGGh3ZUyoXdiVCBXmyXQZ1SjcR1sb_K91S8MoapAj1as3xLCYeNgGiXFkjvCcMeqfsrXXuRIbvTNGVpGDz6eiM3O7r-vRdP_v8ZT9EtlkQ5NdjwQ3QAkhWfQYy0rJ9nRfgFMOoPRA priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGEGgviG8yBjISb2BI_FX7AaFRMU1I44FStDfLcZwtoiRd2iH633N2klaF8sJrbCcn3-9859j3O4ReSikYlwBer3hJeMEc0akMCcwllcxKLWlIcD77LE-n_NO5ON9DQ7mjfgIXO7d2oZ7UtJ29-XW1eg8G_65LGVdvFzyaO3gfwsMOhqxuoJsUPGO44nXWh_txZWYaNjS8z53ZPfQA3WYjxSCqybZcVWT03xWG_n2b8o8j1eipTu6iO32IiY87TNxDe76-j251RSdXD9B8Eiljr1tPggsrcLG5N4RtXeA5LIJ9viTekIHjpsQQLOLJ8ZcJGTffCMVsTGbVd48j1wO8Clf1ZZXDEtHiRfWjbpatn_2s2odoevLx6_iU9HUXiBM8WxLhnFAldSNapiK3LnOO2lJLLUTuM8dormRWaOFsEf4baStVzm0GK1XBFYCCPUL7dVP7JwhTl-WZTEtlZcpLm9rCgclbJrUSqfdpgl4NU2zmHb2GicfiTJlONwZ0Y6JuzCpBH4IW1j0DNXZ80LQXprc0Y6nywgW6U0XB81LtRjoFuSnjIGFZJOho0KEZ4GZg3ygDU2AmEvRi3QyWFo5PbO2b69hnxEZaU5mgx53K15IMkEmQ2gLDlqjbLXV1Gdm8Q6FloSkMfT3gZiPXv-fi8P-_9BQd0ID4cC-HHaF9QJ1_BqHVMn8e7eU3BkkgFw priority: 102 providerName: Scholars Portal – databaseName: SpringerOpen dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagCIkLKu-0BRmJG1gkfsU-loiqQoIDS1FvluPYatSSrHa3SPvvO3ayuwq0h15jOxr5m_GMPZ7PCH2QUjAuQXm94oHwhjmicxkLmAOVzEotaSxw_v5Dnp7xb-fifKTJibUwk_w9U5-XPJkyeBbC4-6ErB-iR-CDy6jNlay25ymR6VxxPtbF3D504nsSRf9tceX_1yP_yZEm13Oyj56OMSM-HkB-hh747jl6PLwiuX6B5rPEAXu98CT6pAY3u4tA2HYNnsOqNhZA4h27N-4DhugPz45_zkjV_yYUs4pctZceJ_IG-BVuu4u2Bptf4GX7p-tXC3_1t128RGcnX39Vp2R8SIE4wYsVEc4JFagrachFbV3hHLVBSy1E7QvHaK1k0WjhbBMPgrSVqua2gKWn4QpQZq_QXtd3_g3C1BV1IfOgrMx5sLltHNiwZVIrkXufZ-jjZorNfODLMCnPzZQZADEAiEmAmHWGvkQUtj0j13X6ACpgRtMxliovXOQvVRRcKdWu1DnITRkHCUOToaMNhmY0wKWBjaCM1H-FyND7bTOYTsyH2M7316lPyUqtqczQ6wHyrSQMJgIi2yJDaqIME1GnLV17kei548vJQlMY-mmjNzu57p6Lg_t1P0RPaFTteLmGHaE90DT_FuKjVf0uGcYNv5UIgw priority: 102 providerName: Springer Nature |
| Title | Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir |
| URI | https://link.springer.com/article/10.1038/s41467-023-42102-y https://www.ncbi.nlm.nih.gov/pubmed/37833261 https://www.proquest.com/docview/2876793715 https://www.proquest.com/docview/2877379926 https://pubmed.ncbi.nlm.nih.gov/PMC10575921 https://doaj.org/article/a28e5c09138247129c790be1234763fd |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLbaTpv6Mu0-ti7ypL1tNOAb9mOKmlWRUlXNOvUNGWNWtASiJJ2Uf79jB5Jll5e9gAQIjjjfudg-5zNCH4TglAkAr5WsDFlBTagi4RqYSyKoFkoQ1-A8vhQXN2x0y28PkOh6YXzRvsmr03o6O62rO19bOZ-Zflcn1r8ap25vWq5I3D9EhxB_fxmje_9LFQxbWNshE1HZXzLvDyA8hcwNccL1MXpEE0khd4n3ApLn7f9bsvlnzeRvC6c-Hg2foMdtIokHG4GfogNbP0MPN1tLrp-j-cQTw94vbOgCVYGLXXUQ1nWB5-Dq2q5IvKP8xk2JISXEk8H1JEybryHBNA2n1XeLPaMDvApX9V2VgyNY4GU1q5vVwk5_VIsX6GZ4_iW9CNvdFULDWbwKuTFclsQkpIx4rk1sDNGlEorz3MaGklyKuFDc6MLNDiktZM50DP6oYBJUT1-io7qp7WuEiYnzWESl1CJipY50YcCwNRVK8sjaKEAfu1-czTckGplf_KYy2-gmA91kXjfZOkBnTgvbJx0Btr_QLL5lLQwyTaTlxpGaSgLxlSiTqAjkJpSBhGURoJNOh1lrlcsMRofC8QHGPEDvt7fBntwiia5tc--fSWiiFBEBerVR-VaSDjIBkntg2BN1_w5A2HN2d5AN0KcONzu5_v0v3vz_l96iY-IQ76pv6Ak6AtTZd5BArfIeWM1tAkc5_NxDDwaD0WQE57Pzy6truJqKtOenJuA4ZrLnresnIoIgIQ |
| link.rule.ids | 230,314,727,780,784,864,885,2102,2221,12056,12765,21388,24318,27924,27925,31719,31720,33373,33374,33744,33745,41120,42189,43310,43600,43805,51576,53791,53793,73745,74035,74302 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLagE4IXxJ3AACPxBtYS32o_oa3aVGCr0LqhvVmO7bCIkZS0Q-q_x3bcVuX2GifRic815_h8B4A3nDNCuRdeJ2iFqCUGyZyHBuYKc6K55Dg0OJ9M-PicfrxgFynhNk_HKlc2MRpq25qQI9_zkT0PWG4Fez_7gcLUqFBdTSM0boKdgJzOBmDn4HDy-XSdZQn454LS1C2TE7E3p9E2eFeFaPjdQcstjxSB-_8Wbf55aPK3yml0SEf3wN0UScL9nvX3wQ3XPAC3-tmSy4dgNo3IsNedQ8FTWWg3x4OgbiyceVuX2iLhBvMbthX0MSGc7p9O0aj9gjAkI3RVf3MwQjr4V8G6uaxLbwk6OK-_N-2ic1c_6-4ROD86PBuNURqvgAyjxQIxY5iosBniKmelNoUxWFeSS8ZKVxiCS8ELK5nRNqSHpOaipLrwBslS4XlPHoNB0zbuKYDYFGXB80pontNK59oar9macClY7lyegberLVazHkVDxeo3EapniPIMUZEhapmBg8CF9Z0BATteaLuvKimU0lg4ZgKqqcDewWJphjL3dGNCPYWVzcDuiocqqeVcbYQoA6_Xy16hQpVEN669jvcMyVBKzDPwpGf5mhLiN8LHu0UGxJYwbJG6vdLUlxG0O8xTZhL7R9-t5GZD17_34tn_P-MVuD0-OzlWxx8mn56DOziIdThuQ3bBwEuZe-EjpkX5MqnFL6I0E5U |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLagE4gXxHUEBhiJN7CW-Fb7CW1l1bhV08rQ3izHcVjESErbIfXfc-y6rcrtNU6iE59rfM75DkIvpRSMSxBer3hNeMUc0bkMDcw1lcxKLWlocP40ksdn_P25OE_1T7NUVrmyidFQV50LZ-T7ENnLgOVWiP06lUWcvB2-mfwgYYJUyLSmcRrX0Q54xZz20M7h0ejkdH3iErDQFeepcyZnan_Go50At0V4-PUhiy3vFEH8_xZ5_llA-VsWNTqn4R10O0WV-GApBnfRNd_eQzeWcyYX99FkHFFir6aeBK9V4WpTKoRtW-EJ2L3UIok3-N-4qzHEh3h8cDomg-4LoZgNyGXzzeMI7wCvwk170ZRgFaZ41nxvu_nUX_5spg_Q2fDo8-CYpFELxAlezIlwTqiauj6tc1FaVzhHba2lFqL0hWO0VLKotHC2CkdF2kpVcluAcaq4AjlgD1Gv7Vr_CGHqirKQea2szHltc1s50HLLpFYi9z7P0KvVFpvJElHDxEw4U2bJEAMMMZEhZpGhw8CF9Z0BDTte6KZfTVIuY6nywgWEU0XB2VLt-joHuinjQGFdZWhvxUOTVHRmNgKVoRfrZVCukDGxre-u4j191teaygztLlm-poTBRkDsW2RIbQnDFqnbK21zEQG8w2xloSk8-nolNxu6_r0Xj___Gc_RTdAI8_Hd6MMTdIsGqQ6VN2wP9UDI_FMInubls6QVvwCGsxfC |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structure-based+development+and+preclinical+evaluation+of+the+SARS-CoV-2+3C-like+protease+inhibitor+simnotrelvir&rft.jtitle=Nature+communications&rft.au=Jiang%2C+Xiangrui&rft.au=Su%2C+Haixia&rft.au=Shang%2C+Weijuan&rft.au=Zhou%2C+Feng&rft.date=2023-10-13&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2041-1723&rft.volume=14&rft_id=info:doi/10.1038%2Fs41467-023-42102-y&rft_id=info%3Apmid%2F37833261&rft.externalDBID=PMC10575921 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon |